Lunit Partners with Radiobotics to Enhance Diagnostic Synergies in AI Medical Imaging

Lunit enters into a strategic agreement with Radiobotics to distribute Radiobotics' bone fracture detection solution starting from EMEA

Seoul, South Korea, April 29, 2024 -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, recently entered into a strategic partnership with Denmark-based Radiobotics, the leading musculoskeletal (MSK) AI diagnostics provider. The partnership aims to significantly enhance both companies' presence in the AI medical imaging market starting from Europe, the Middle East, and Africa (EMEA), and to offer new value to the sector through the synergies created by combining the complementary strengths of both companies.

As part of this collaboration, Lunit will be the distributor of Radiobotics' RBfracture™, a CE MDR Class IIa-certified AI tool designed for rapid and precise detection of bone fractures on X-ray images. 

This strategic move is poised to generate significant market synergies by combining the unique strengths of both companies. When used alongside RBfracture™, Lunit’s AI-powered chest X-ray screening solution, Lunit INSIGHT CXR, enhances the comprehensive diagnostic capabilities available to healthcare providers, offering a full spectrum of AI-assisted screening that spans lung abnormalities to bone fractures with a single X-ray.

"By joining forces with Radiobotics, we aim to augment the value we deliver to the healthcare market, expanding the reach and efficacy of AI-driven X-ray diagnostics," said Brandon Suh, CEO of Lunit. "This partnership represents a strategic move to meet the growing demand for advanced diagnostic tools across medical practices in the region. Together, we are poised to set new standards in healthcare diagnostics, benefiting providers and patients alike with more accurate and accessible technology."

“We are truly excited to be able to collaborate with a market leader like Lunit, and see how

our solutions complement their products, so the customers can in the end get an easier

access to a more complete offering in X-ray AI analysis”, said Peter Ulvskjold, CEO of

Radiobotics.

The collaboration not only elevates accuracy and adaptability but also substantially improves patient outcomes by offering a holistic assessment of potential health issues across different body areas.

Additionally, the agreement allows Lunit to expand its diagnostic portfolio to include other X-ray diagnostic tools from Radiobotics, such as those for detecting knee osteoarthritis and hip dysplasia, further solidifying its leadership in the AI-based X-ray analysis market.

###

About Lunit

Founded in 2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. We are committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers.

As a medical AI company grounded on clinical evidence, our findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and global conferences, including ASCO and RSNA. 

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io.

About Radiobotics

Based out of Denmark, Radiobotics develops medical AI solutions for MSK x-ray analysis,

with a deliberate focus on being the best trauma x-ray decision support tool globally.

Radiobotics’ fracture detection solution, RBfracture™, can with high precision detect

fractures and other trauma-related findings in x-ray images, aimed at the emergency setting,

enabling support in detection and clinical decisions. For more information, please visit

radiobotics.com.

If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.